Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Core Viewpoint - Eyenovia, Inc. has regained compliance with Nasdaq listing requirements, marking a significant milestone in its efforts to enhance shareholder value and advance the development of its Optejet device [1][2]. Company Overview - Eyenovia, Inc. is focused on developing its proprietary Optejet topical ophthalmic medication dispensing platform, which aims to improve treatment options for chronic front-of-the-eye diseases through enhanced safety, tolerability, and compliance compared to standard eye drops [3]. Strategic Actions - The company has taken steps to restructure and accelerate the development of the Optejet, including a reverse stock split approved by shareholders, which facilitated compliance with Nasdaq's continued listing requirements [2].